CORONA Remedies · Analyst questions, management answers, and the quality of the response where the ledger is available.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
83%
Numeric claims
2
Consistency
mixed
Question ledger
Alankar Garud · Kotak Institutional Equities
directwe are amongst top five or six companies in women's healthcare... we acquired with bioiders about few products in the segment on infertility... we are going to launch a separate team for infertility and entering in the infertility market with this products
Alankar Garud · Kotak Institutional Equities
partialwe are working to develop six seven therapies today like infertility, spine, romato, CNS, dermatology, gastrointestinal... we will unlock each therapy at the right time starting with infertility... our aim is to take the leadership position in that therapy
Alankar Garud · Kotak Institutional Equities
directthe percentage contribution to the R&D will remain less than 2% and today about 100 plus scientists are working in R&D we will expand little but if we grow only revenues like 15% plus that percentage less than 2% will remain less than 2%.
Yug Modi · AP Capital
directwe try to launch the product with little niche or little differentiated manner... we try to take the road of a little differentiated manner try to put a science into it a unmet need of the patients and the medical fertility
Yug Modi · AP Capital
directtoday we have about 3 and a half% contribution with the international business... we will go worldwide except US and Japan as of now to start with... Europe, UK, Australia, New Zealand, Brazil, Mexico, Asia and CIS Russia
Rahul Jivani · IIL Capital Services Limited
directcorona's PCPM per capita per month is about 3.9 months about four lakhs rupees... productivity vise from 2.5 lakh to 8 lakh from the people who have been joined you know 6 to 9 years range
Rahul Jivani · IIL Capital Services Limited
directwe have decided to expand these MR numbers by 5 to 7% on year on year... our endeavor is to grow on 15% on revenue and 20% on PAT
Rahul Jivani · IIL Capital Services Limited
directwe are now going to kickstart the commercial by the Q2 end of Q2 or early of Q3 of FY27... by Q4 of FY27 we're expecting about WH and by that time we will try to take EUGMP inspection
Rahul Jivani · IIL Capital Services Limited
partialwe are constantly evaluating it... we are looking at two three interesting opportunities but nothing concrete as of now after Zidus buyer our first focus is to make this acquisition more meaningful
Niharika Agarwal · Incred Asset Management
directmore or less it is 50/50 but 100 basis point minus in the first half versus 100 basis point... Q3 slightly lesser because of festive season but also 25 to 27% on quarter on quarter
Niharika Agarwal · Incred Asset Management
evasiveour endeavor is about 20% PAT or EPS growth year on year for next four years. We have a plan in place till FY 29
A (first name only) · JM Financial
directthe market shift has been happening in the specialist in each category from semi-urban to metro is increasing heavily... our focus will remain same on the middle of the pyramid specialist
